Cargando…

Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder

Many patients with opioid use disorder do not have successful outcomes during treatment but the underlying reasons are not well understood. An OPRD1 variant (rs678849) was previously associated with methadone and buprenorphine efficacy in African-Americans with opioid use disorder. The objective of...

Descripción completa

Detalles Bibliográficos
Autores principales: Crist*, Richard. C., Phillips, Karran. A., Furnari, Melody. A., Moran, Landhing. M., Doyle, Glenn. A., McNicholas, Laura. F., Cornish, James. W., Kampman, Kyle. M., Preston, Kenzie. L., Berrettini, Wade. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486881/
https://www.ncbi.nlm.nih.gov/pubmed/30368523
http://dx.doi.org/10.1038/s41397-018-0065-x
_version_ 1783414401155465216
author Crist*, Richard. C.
Phillips, Karran. A.
Furnari, Melody. A.
Moran, Landhing. M.
Doyle, Glenn. A.
McNicholas, Laura. F.
Cornish, James. W.
Kampman, Kyle. M.
Preston, Kenzie. L.
Berrettini, Wade. H.
author_facet Crist*, Richard. C.
Phillips, Karran. A.
Furnari, Melody. A.
Moran, Landhing. M.
Doyle, Glenn. A.
McNicholas, Laura. F.
Cornish, James. W.
Kampman, Kyle. M.
Preston, Kenzie. L.
Berrettini, Wade. H.
author_sort Crist*, Richard. C.
collection PubMed
description Many patients with opioid use disorder do not have successful outcomes during treatment but the underlying reasons are not well understood. An OPRD1 variant (rs678849) was previously associated with methadone and buprenorphine efficacy in African-Americans with opioid use disorder. The objective of this study was to determine if the effect of rs678849 on opioid use disorder treatment outcome could be replicated in an independent population. Participants were recruited from African-American patients who had participated in previous studies of methadone or buprenorphine treatment at the outpatient treatment research clinic of the NIDA Intramural Research Program in Baltimore, MD, USA between 2000 and 2017. Rs678849 was genotyped retrospectively and genotypes were compared to urine drug screen results from the previous studies for opioids other than the one prescribed for treatment. Genotypes were available for 24 methadone patients and 55 buprenorphine patients. After controlling for demographics, the effect of rs678849 genotype was significant in the buprenorphine treatment group (RR = 1.69, 95% confidence interval (CI) 1.59–1.79, p = 0.021). Buprenorphine patients with the C/C genotype were more likely to have opioid-positive drug screens than individuals with the C/T or T/T genotypes, replicating the original pharmacogenetic finding. The effect of genotype was not significant in the methadone group (p = 0.087). Thus, genotype at rs678849 is associated with buprenorphine efficacy in African-Americans being treated for opioid use disorder. This replication suggests that rs678849 genotype may be a valuable pharmacogenetic marker for deciding which opioid use disorder medication to prescribe in this population.
format Online
Article
Text
id pubmed-6486881
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-64868812019-04-27 Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder Crist*, Richard. C. Phillips, Karran. A. Furnari, Melody. A. Moran, Landhing. M. Doyle, Glenn. A. McNicholas, Laura. F. Cornish, James. W. Kampman, Kyle. M. Preston, Kenzie. L. Berrettini, Wade. H. Pharmacogenomics J Article Many patients with opioid use disorder do not have successful outcomes during treatment but the underlying reasons are not well understood. An OPRD1 variant (rs678849) was previously associated with methadone and buprenorphine efficacy in African-Americans with opioid use disorder. The objective of this study was to determine if the effect of rs678849 on opioid use disorder treatment outcome could be replicated in an independent population. Participants were recruited from African-American patients who had participated in previous studies of methadone or buprenorphine treatment at the outpatient treatment research clinic of the NIDA Intramural Research Program in Baltimore, MD, USA between 2000 and 2017. Rs678849 was genotyped retrospectively and genotypes were compared to urine drug screen results from the previous studies for opioids other than the one prescribed for treatment. Genotypes were available for 24 methadone patients and 55 buprenorphine patients. After controlling for demographics, the effect of rs678849 genotype was significant in the buprenorphine treatment group (RR = 1.69, 95% confidence interval (CI) 1.59–1.79, p = 0.021). Buprenorphine patients with the C/C genotype were more likely to have opioid-positive drug screens than individuals with the C/T or T/T genotypes, replicating the original pharmacogenetic finding. The effect of genotype was not significant in the methadone group (p = 0.087). Thus, genotype at rs678849 is associated with buprenorphine efficacy in African-Americans being treated for opioid use disorder. This replication suggests that rs678849 genotype may be a valuable pharmacogenetic marker for deciding which opioid use disorder medication to prescribe in this population. 2018-10-27 2019-06 /pmc/articles/PMC6486881/ /pubmed/30368523 http://dx.doi.org/10.1038/s41397-018-0065-x Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Crist*, Richard. C.
Phillips, Karran. A.
Furnari, Melody. A.
Moran, Landhing. M.
Doyle, Glenn. A.
McNicholas, Laura. F.
Cornish, James. W.
Kampman, Kyle. M.
Preston, Kenzie. L.
Berrettini, Wade. H.
Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder
title Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder
title_full Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder
title_fullStr Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder
title_full_unstemmed Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder
title_short Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder
title_sort replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in african-americans with opioid use disorder
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486881/
https://www.ncbi.nlm.nih.gov/pubmed/30368523
http://dx.doi.org/10.1038/s41397-018-0065-x
work_keys_str_mv AT cristrichardc replicationofthepharmacogeneticeffectofrs678849onbuprenorphineefficacyinafricanamericanswithopioidusedisorder
AT phillipskarrana replicationofthepharmacogeneticeffectofrs678849onbuprenorphineefficacyinafricanamericanswithopioidusedisorder
AT furnarimelodya replicationofthepharmacogeneticeffectofrs678849onbuprenorphineefficacyinafricanamericanswithopioidusedisorder
AT moranlandhingm replicationofthepharmacogeneticeffectofrs678849onbuprenorphineefficacyinafricanamericanswithopioidusedisorder
AT doyleglenna replicationofthepharmacogeneticeffectofrs678849onbuprenorphineefficacyinafricanamericanswithopioidusedisorder
AT mcnicholaslauraf replicationofthepharmacogeneticeffectofrs678849onbuprenorphineefficacyinafricanamericanswithopioidusedisorder
AT cornishjamesw replicationofthepharmacogeneticeffectofrs678849onbuprenorphineefficacyinafricanamericanswithopioidusedisorder
AT kampmankylem replicationofthepharmacogeneticeffectofrs678849onbuprenorphineefficacyinafricanamericanswithopioidusedisorder
AT prestonkenziel replicationofthepharmacogeneticeffectofrs678849onbuprenorphineefficacyinafricanamericanswithopioidusedisorder
AT berrettiniwadeh replicationofthepharmacogeneticeffectofrs678849onbuprenorphineefficacyinafricanamericanswithopioidusedisorder